

B. In the Claims

This listing of the claims supersedes all previous listings.

1. (Currently Amended) A method of aiding in the diagnosis of ~~the~~ A neoplastic condition of a lung cell, comprising detecting the presence of an overexpressed proto-oncogene ~~selected from the group consisting of b-myb, p67, PGP9.5 and 8-oxo-dGTPase~~, in a lung cell sample, wherein the overexpression is indicative of the neoplastic condition of the lung cell.

2. (Withdrawn) The method of claim 1, wherein the proto-oncogene is b-myb.

3. (Cancelled).

4. (Withdrawn) The method of claim 1, wherein the proto-oncogene is 8-oxo-dGTPase.

5. (Withdrawn) The method of claim 1, wherein the proto-oncogene is p67.

6. (Withdrawn) The method of claim 1, wherein the presence of the overexpressed proto-oncogene is determined by detecting the quantity of mRNA transcribed from the proto-oncogene.

7. (Withdrawn) The method of claim 2, wherein the detecting is determined by probing the sample with a probe or primer comprising the sequence TGCTGCCCTG (SEQ. ID No.1) or its complement.

8. (Withdrawn) The method of claim 3, wherein the detecting is determined by probing the sample with a probe or primer comprising the sequence CAGTCTAAAA (SEQ. ID No.2) or its complement.

9. (Withdrawn) The method of claim 4, wherein the detecting is determined by probing the sample with a probe or primer comprising the sequence TGGCCCGACG (SEQ. ID No.3) or its complement.

10. (Withdrawn) The method of claim 5, wherein the detecting is determined by probing the sample with a probe or primer comprising the sequence TAATACTTTT (SEQ ID NO. 4) or its complement.

11. (Withdrawn) The method of claim 6, wherein the presence of the overexpressed proto-oncogene is determined by detecting the quantity of cDNA produced from the reverse transcription of the mRNA.

12. (Amended) The method of claim 1, wherein the ~~presence~~presence of the overexpressed proto-oncogene PGP9.5 is determined by detecting the quantity of the polypeptide or protein encoded by the proto-oncogene.

13. (Amended) The method of claim 12, wherein the ~~lung cancer~~ neoplastic condition of a lung cell is non-small cell lung cancer.

14. (Withdrawn) A screen for a potential therapeutic agent for the reversal of the neoplastic condition of a lung cell wherein the cell is characterized by overexpression of a proto-oncogene selected from the group consisting of b-myb, p67, PGP9.5 and 8-oxo-dGTPase comprising contacting a sample with an effective amount of a potential agent and assaying for reversal of the neoplastic condition.

15. (Withdrawn) The screen of claim 14, wherein the proto-oncogene is b-myb.

16. (Withdrawn) The method of claim 14, wherein the proto-oncogene is PGP9.5.

17. (Withdrawn) The method of claim 14, wherein the proto-oncogene is 8-oxo-dGTPase.

18. (Withdrawn) The method of claim 14, wherein the proto-oncogene is p67.

19. (Withdrawn) A method for reversing the neoplastic condition of a lung cell, wherein the cell is characterized by overexpression of a proto-oncogene comprising contacting the cell with an agent identified by the method of claim 14.

20. (Withdrawn) The method of claim 19, wherein the proto-oncogene is b-myb.
21. (Withdrawn) The method of claim 19, wherein the proto-oncogene is PGP9.5.
22. (Withdrawn) The method of claim 19, wherein the proto-oncogene is 8-oxo-dGTPase.
23. (Withdrawn) The method of claim 19, wherein the proto-oncogene is p67.
24. (Withdrawn) The method of claims 19, wherein the agent is anti-sense RNA that specifically inhibits the overexpression of the proto-oncogene.
25. (Withdrawn) A probe or primer to detect the presence of b-myb, comprising sequence TGCTGCCCTG (SEQ. ID No.1) or its complement.
26. (Withdrawn) A probe or primer to detect the presence of PGP9.5, comprising sequence CAGTCTAAAA (SEQ. ID No.2) or its complement.
27. (Withdrawn) A probe or primer to detect the presence of 8-oxo-dGTPase, comprising sequence TGGCCCGACG (SEQ. ID No.3) or its complement.
28. (Withdrawn) A probe or primer to detect the presence of p67, comprising sequence TAATACTTTT (SEQ ID NO. 4) or its complement.
29. (Withdrawn) A solid phase support comprising the probes or primers of claims 25 through 28, or their complements.
30. (Withdrawn) A kit for use in a diagnostic method according to claim 1 comprising in suitable packaging:
one or more polynucleotides selected from the group consisting of b-myb, p67, PGP9.5 and 8-oxo-dGTPase immobilized on a solid support and
a reagent suitable for hybridizing a sample suspected of containing the lung cancer cell.